Related Experiment Videos
Morbidity in valvular heart replacement: risk factors of systemic emboli and thrombotic obstruction
M Abdelnoor1, K V Hall, S Nitter-Hauge
1Dept. of Cardiovascular Surgery and Cardiology, Rikshospitalet, University of Oslo-Norway.
Insights
Systemic emboli risk after heart valve replacement varies by procedure type. Patient factors like aortic regurgitation, age, and sex significantly influence thromboembolism risk, highlighting personalized risk assessment needs.
Area of Science:
- Cardiovascular Surgery
- Biomedical Engineering
- Clinical Epidemiology
Background:
- Heart valve replacement is a common procedure for valvular heart disease.
- Thromboembolism (TE) is a significant complication following prosthetic heart valve implantation.
- Understanding risk factors for TE is crucial for patient management and outcomes.
Purpose of the Study:
- To evaluate the incidence of systemic emboli and thrombotic obstruction after different types of heart valve replacement.
- To identify patient-related risk factors for thromboembolism in patients undergoing aortic valve replacement (AVR) and mitral valve replacement (MVR).
Main Methods:
- Retrospective cohort study of 839 patients undergoing valvular heart replacement between June 1977 and May 1985.
- Calculation of linearized rates of systemic emboli and thrombotic obstruction.
- Analysis using Cox regression to identify risk factors for TE.
Main Results:
- Linearized rates of TE were 1.4/100 pts/year for AVR, 2.2/100 pts/year for MVR, and 3.00/100 pts/year for Double Valve Replacement (DVR).
- Five-year TE-free survival was 95% for AVR and 92% for MVR.
- Risk factors for TE in AVR included aortic regurgitation and age; in MVR, female sex was a predictor.
Conclusions:
- The risk of thromboembolism after heart valve replacement is influenced by the type of prosthesis and patient-specific factors.
- Patient characteristics, such as age, sex, and pre-existing aortic regurgitation, are important predictors of TE morbidity.
- Personalized risk assessment and management strategies are essential for improving outcomes in patients with prosthetic heart valves.
Abstract:
A study on a cohort of 839 patients with valvular heart replacement between June 1977 and May 1985 showed that the linearized rates of systemic emboli and thrombotic obstruction were 1.4/100 pts/year for Aortic Valve Replacement (AVR), 2.2/100 pts./year for Mitral Valve Replacement, and 3.00/100 pts./year for Double Valve Replacement (DVR). The 5-year free-from-thromboembolism (TE) survival was 95% for AVR and 92% for MVR. The hazard function (the instantaneous risk) for TE peaked in the first six months after operation for AVR and MVR. Another analysis using the Cox regression model to estimate risk factors of systemic emboli and thrombotic obstruction pinpointed two factors in the AVR group: presence of aortic regurgitation (AR) and age at operation. In the MVR group the sole predictor covariate was sex of the patients, with a higher hazard for females. Our results underline the importance of patient-related factors besides the type of prosthesis as predictors of morbidity from TE.